In this study we have examined if the i. 
We have suggested previously that the dihydropyridine (DHP) binding site on neuronal L-type voltagesensitive Ca 2; channels (VSCC) may be a target site for i.v. anaesthetic agents 1 . It is not known if other binding sites on the L-type VSCC, such as verapamil or diltiazem sites, are also involved. However, Maze and colleagues reported that verapamil significantly augmented anaesthetic potency (see Hirota and Lambert 1 2 ). As the verapamil binding site resides, together with the DHP binding site, on the ␣1 subunit of the channel, we have examined if this site is a target for i.v. anaesthetic agents.
Materials and methods
Female Wistar rats (250-300 g) were stunned and then decapitated. The brain was removed rapidly, the cerebrocortex detached from its internal structures, and homogenized at 4 ЊC using a tissue Tearor (set- ) and ketamine (500 mmol litre -1 stock in distilled water). Appropriate solvent concentrations were added to control tubes. Non-specific binding was defined in the presence of excess (10 -6 mol litre After incubation, each sample was filtered under vacuum through Whatman GF/B filters using a Brandell cell harvester to separate bound and free radioactivity. Filter retained (bound) radioactivity was extracted for at least 8 h in 4 ml of scintillation fluid and then estimated using a beta scintillation counter. The estimated radioactivity was quench corrected with an average [ 
Discussion
Two studies 1 2 have suggested that L-type VSCC may be involved in the mechanism of general anaesthesia because L-type VSCC blockers enhanced anaesthetic potency. Previous work from our laboratory . Collectively, our data suggest that a specific region of the L-channel may act as a target for i.v. agents.
However, verapamil has been reported to decrease the MAC for halothane in dogs and significantly augment the anaesthetic potency of dexmedetomidine or ketamine (see Hirota and Lambert 1 2 ). Chikhale, Burton and Borchard 6 suggested that verapamil caused a significant increase in the permeability of the blood-brain barrier, although verapamil itself does not pass the blood-brain barrier. Therefore, this enhancement of anaesthetic potency may not be a direct interaction with the channel (consistent with our data) but may simply enhance agent delivery to the CNS target site(s).
In conclusion, these data indicate that i.v. anaesthetic agents are unable to interact with the verapamil binding site on L-type VSCC at clinically relevant concentrations. 
